Tests magnetic brain stimulation for depression in adults with autism
Tests a single magnetic brain stimulation session in adults with autism and depression.
Plain-language title generated from the registry record
Registry title: Transcranial Magnetic Stimulation (TMS) to Treat Depression in Autism Spectrum Disorder
Key facts
- Where
- New Haven, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 40 years old?
Source: NCT06142955, who can take part
Where in United States
- Yale Psychiatric HospitalNew Haven, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Yale University
- Trial code
- NCT06142955
- Record updated
- 16 July 2026
- Original description
This study will assess clinical and behavioral measures along with electroencephalogram (EEG), event-related potentials (ERPS), and eye-tracking (ET) prior to and following a single intermittent Theta Burst Stimulation (iTBS) session to provide preliminary insight into the potential of TMS as an intervention for depression in individuals with Autism Spectrum Disorder (ASD).Read full original descriptionShow less
Neuromodulation for Depression in Autism Spectrum Disorder
This study will assess clinical and behavioral measures along with electroencephalogram (EEG), event-related potentials (ERPS), and eye-tracking (ET) prior to and following a single intermittent Theta Burst Stimulation (iTBS) session to provide preliminary insight into the potential of TMS as an intervention for depression in individuals with Autism Spectrum Disorder (ASD).
Inclusion: Individuals from Yale University and the surrounding community who are between the ages of 18 and 40 years old with or without a diagnosis of depression. Or individuals between the ages of 18 and 40 years old with a diagnosis of autism spectrum disorder, autistic disorder, PDD NOS, or Asperger syndrome with or without a diagnosis of depression; A depression score on the HDRS-17 of at least 20 will be used as a cut-off for depression; Participants are unmedicated or on stable medication treatment for at least two weeks; Willingness and ability to participate in an EEG and eye-tracking procedure; Provision of signed and dated informed consent.
Exclusion: Participants taking prescription medications that may affect cognitive processes under study; Participants who have taken alcohol or recreational drugs within the preceding 24 hours prior to the scheduled study visit as determined by the urine toxicology test; Participants with a history of prior TMS therapy or use of an investigational drug within 12 weeks of visit; Participants reporting significant head trauma or serious brain illness; Participants with major psychiatric illness that would preclude completion of study measures. Participants with diagnosis of a psychotic or bipolar illness with be excluded; Participants with a history of serious medical illness, stroke, seizures, epileptiform EEG abnormalities, or family history of epilepsy; Participants taking any medication that may increase their risk of seizures; Participants with a history of substance or alcohol abuse or dependence in the past 6 months; Participants with a history of metalworking or injury by shrapnel or metallic objects; Participants unable to provide signed informed consent; Participants with a significant risk of suicide or a h/o suicide attempt in the last 6 months. Participants with active suicidal ideation will be excluded from the study; Females of known/suspected pregnancy or who test positive on a pregnancy test; Participants with an IQ below 80 (as confirmed by the WASI, Wechsler Abbreviated Scale of Intelligence).